From November 1st to 3rd, the "Making Innovation Sustainable" - the 15th China Pharmaceutical Entrepreneur, Scientist, and Investor Conference, sponsored by the China Pharmaceutical Enterprise Management Association and the China Pharmaceutical Biotechnology Association, among others, was held in Hangzhou with great pomp. As the event with the highest specifications, strongest influence, and largest scale in China's pharmaceutical industry, the conference gathered approximately 1,500 participants, including government officials, entrepreneurs, scientists, investors from the bio-pharmaceutical industry, and media representatives.
During the conference, the 2023 "Top 100 Chinese Pharmaceutical Innovation Enterprises" series of rankings, the "50 Best Practice Cases of Traditional Chinese Medicine Inheritance and Innovation in 2023" and other rankings, organized and selected by the China Pharmaceutical Enterprise Management Association and Healthcare Executive, were officially released. Kanion Pharmaceutical Industry was on the list of "Top 100 Chinese Pharmaceutical Innovation Enterprises" and "Top 10 Most Investment-worthy Chinese Pharmaceutical Listed Enterprises", and was awarded the title of "Best Practice Case of Traditional Chinese Medicine Inheritance and Innovation".
The "Top 100 Chinese Pharmaceutical Innovation Enterprises" list is jointly launched by Healthcare Executive and Clarivate Analytics. The list is evaluated based on four indicators: the number of authorized patents, the total number of patent citations, the number of clinical trials, and the number of approved and marketed innovative drugs. The list aims to tap into innovation forces, disseminate innovation experience, and deeply analyze innovation capability and sustainability of China's pharmaceutical industry. As the first tier representing China's pharmaceutical innovation capabilities, the Top 100 Innovative companies are the main force driving the transformation and upgrading of China's pharmaceutical industry, and building industrial competitiveness. They also provide valuable experience and benchmarks for later generations to learn from.
The Most Investment-worthy Enterprise List selects the top 100 pharmaceutical listed companies as candidate companies based on the total evaluation score of seven indicators across three dimensions of objective data: industry (revenue, revenue growth rate, and R&D expenditure), management (net profit attributable to shareholders and average return on equity), and capital (annual average market value and annual average market value growth rate). Among these top 100 listed companies, the top 10 are further screened based on their market value growth rate from 2020 to 2022.
In the past three years, Kanion Pharmaceutical has marketed four new traditional Chinese medicines, namely Bone Acesodyne Gel, Yinqiao Heat-clearing Tablets, Cold-dispelling Dehumidification Granules and Linggui Zhugan Granules. The R&D expense rate of the company has also been rising. This honor of being included in the "Top 10 Most Investment-worthy Chinese Pharmaceutical Listed Enterprises" list is a recognition of the company's outstanding performance in traditional Chinese medicine innovation strength and management.
The goal of the "50 Best Practice Cases for Traditional Chinese Medicine Inheritance and Innovation in 2023" is to comprehensively showcase and explore the cultural charm and unique value of traditional Chinese medicine, establish benchmarks for traditional Chinese medicine inheritance and innovation practice, and explore the development direction of traditional Chinese medicine enterprise inheritance and innovation. This selection lasted for five months, with cases sourced from public solicitation and expert recommendations. The evaluation criteria were based on the work and achievements of enterprises in five sub levels of "cultural inheritance, diagnosis and treatment inheritance, traditional Chinese medicine resources, R&D innovation, and modernization innovation". As a result, 50 best practice cases in traditional Chinese medicine inheritance and innovation from Chinese medicine enterprises were selected.
In recent years, "inheritance and innovation of traditional Chinese medicine" has become a hot topic in the pharmaceutical industry. Kanion Pharmaceutical has also continued to explore in the practice of inheritance and innovation of traditional Chinese medicine, inheriting the essence, upholding the integrity, maintaining the innovation, and accelerating the modernization of traditional Chinese medicine. In this process, it has accumulated a wealth of excellent practical experience. The title of "Best Practice Case for Traditional Chinese Medicine Inheritance and Innovation" awarded this time is also a recognition of Kanion Pharmaceutical's practical experience from all sectors of society. We hope to create an excellent model for the high-quality development of the industry!
Inheriting and developing traditional Chinese medicine requires innovation. Looking into the future, the prospect for high-quality development of the modernized traditional Chinese medicine industry is vast. As a leading enterprise in traditional Chinese medicine R&D innovation, Kanion Pharmaceutical will adhere to the innovative development of traditional Chinese medicine. By continuously developing "uniform, stable, safe, and effective" innovative traditional Chinese medicines, the company will fully play the leading role in technological innovation, product research and development, and achievement industrialization, and strive to create a new situation for high-quality development in the traditional Chinese medicine industry, making greater contributions to enhancing the health and well-being of the entire population.
